"This is the data SRPT decided was worthy of the gamble to play with the lives of the DMD community"
Well, they can only work with what they have. I'd say it's been a good gamble for them insofar as capital appreciation of the asset. In the end, they're just a legitimate biotech conducting research with a clear conscience, and a fat paycheck. There are far worse scenarios. Bravo to them for getting it as high as they did and for so long.
Did you read the report? FDA argues kids deteriorate in ambulatory function either way. It would seem they take into consideration the parents' bias at the end of their report, but still, the answer is no. Seems pointless the way they leak their findings before the advisory panel. Takes the fun out of it... might be priced in, though somehow I doubt it. Let's reconvene after the inevitable.
You don't even need research training. It is beyond damning for the 22nd. That made it clear that the rules that apply for AA still require a strong evidentiary standard. If one reads that (as I did), looking for silver lining, they won't find a thing. Well, maybe the lack of patients that the FDA hammers on could argue for the potential in the long term. There's not a chance in hell for accelerated approval.
Must be hard to sell in 14s. I held in early 2015, as much as it hurt, and sold at $30, then lamented not holding on as it climbed to ~42 in Oct. But... reading that scathing FDA report (always seems F'ed up when they do this before the advisory panel) and looking at today's market cap... still pretty rich. I think you made a wiser decision than holding through 2015, though, I might be a buyer under 5.